NBGH recognizes employers that promote healthy living
WASHINGTON A nonprofit organization has awarded more than 60 employers for promoting healthy living.
The National Business Group on Health announced Wednesday that it had recognized 63 large employers as the winners of the “2009 Best Employers for Healthy Lifestyles” award.
“We are proud to recognize 63 large employers for their unparalleled commitment to a healthy workplace and for making their employees’ health and well-being a top priority,” NGBH president Helen Darling said. “Employers know first-hand that a healthy workforce is essential to increasing productivity and to maintaining a competitive edge in the new global economy.”
Companies that won the award – given in Platinum, Gold and Silver categories – included Hannaford Supermarkets, Boehringer Ingelheim Pharmaceuticals, CVS Caremark, General Mills, Wal-Mart, Cardinal Health, Meijer and Target.
GSK to develop inflammatory disease treatments with Chroma Therapeutics
LONDON British drug maker GlaxoSmithKline will collaborate with fellow British pharmaceutical company Chroma Therapeutics to develop treatments for such inflammatory diseases as rheumatoid arthritis.
GSK announced Tuesday that it would work with Chroma to use Chroma’s proprietary esterase-sensitive motif technology, which uses amino acid esters to make drugs target cells that cause inflammatory diseases.
Under the terms of the collaboration with GSK’s Center of Excellence for External Drug Discovery, Chroma will seek to discover new pharmaceutical drugs in four discovery and development programs, receiving a “significant” up-front cash payment and an equity financing investment by GSK, as well as potential milestones, royalties and option fees, including possibly more than $1 billion in milestones.
“This agreement marks GSK’s continued efforts to access the best science and technology platforms worldwide,” GSK VP and head of the European CEEDD Shelagh Wilson stated.
Takeda completes acquisition of IDM Pharma
OSAKA, Japan Japanese drug maker Takeda Pharmaceutical Co. completed its tender offer for a company that develops cancer drugs.
Takeda announced Tuesday that it had completed its tender offer to acquire all outstanding shares of IDM Pharma for $2.64 per share, with about 86% of IDM shares tendered.
The two companies originally agreed to the acquisition in May, with Takeda showing particular interest in IDM’s malignant bone cancer drug Mepact (mifamurtide), which European regulators approved in March for marketing in the European Union, Iceland, Liechtenstein and Norway.